Atara Biotherapeutics ATRA Declines 697 Support Test Looms as Biotech Sentiment Softens Political Commentary Adds to Market Uncertainty Amid Leadership Concerns NRC Q1 2026 Earnings EPS of 021 Highlights Quiet Quarter Amid Limited Disclosure DeepSeek AI Draws Silicon Valley Praise Despite Chip Constraints